Adenovirus, Coronavirus, Human Metapneumovirus (hMPV), Influenza Viruses, Parainfluenza Virus (PIV), Respiratory Syncytial Virus (RSV), Rhinovirus, Severe Acute Respiratory Syndrome Coronavirus 2
Conditions
Keywords
hMPV, RSV, PIV, SarsCov2, respiratory viruses, older adults, prognosis, morbidity, mortality
Brief summary
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations. Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases. The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
Interventions
OTHERRespiratory viral infection
Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 65 years or older * Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4. * Hospitalized in an Acute Medicine/Geriatrics Unit * Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person. * Affiliated to a social security scheme
Exclusion criteria
* Refusal to participate * Patient deprived of liberty by a judicial or administrative decision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants with death and/or organ decompensation at Day 180 | From baseline Day 0 to Day 180 | Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants who died | From baseline Day 0 to Day 30, Day 180, Day 365 | Proportion of participants who died from any cause during follow-up. |
| Proportion of participants with major organ decompensation | From baseline Day 0 to Day 30, Day 180, Day 365 | Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation. |
| Proportion of participants with unplanned hospital readmission | From baseline Day 0 to Day 30, Day 180, Day 365 | Proportion of participants experiencing an unplanned hospital readmission during follow-up. |
| Proportion of participants developing a lower respiratory tract infection | From baseline Day 0 to Day 30 | Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection. |
| Change from baseline in functional dependency assessed by ADL and/or iADL scores | Baseline Day 0, Day 30, Day 180, Day 365 | Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and/or Instrumental Activities of Daily Living (iADL) scores. |
| Change from baseline in sarcopenia risk assessed by SARC-F score | Baseline Day 0, Day 30, Day 180, Day 365 | Change in sarcopenia risk from baseline, assessed using the SARC-F score. |
| Change from baseline in quality of life assessed by EQ-5D-3L | Baseline Day 0, Day 30, Day 180, Day 365 | Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire. |
| Number and type of bacterial and viral co-infections | Baseline Day 0 to D7 | Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection. |
| Change in respiratory viral load between Day 0 and Day 7 | From Day 0 to Day 7 | Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants. |
| Proportion of participants with death and/or major organ decompensation at Day 30 | From baseline Day 0 to Day 30 | Proportion of participants who died and/or experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections. |
Contacts
CONTACTGiovanna Mrs MELICA, MD, PhD
Outcome results
None listed